Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

NCT00947349 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
Pharmacokinetics

Interventions

DRUG: ribavirin (RBV)
DRUG: pegylated interferon (PegIFN) alfa-2a
DRUG: pegylated interferon (PegIFN) alfa-2a
DRUG: ribavirin (RBV)
DRUG: BI 201335 NA low placebo
DRUG: pegylated interferon (PegIFN) alfa-2a
DRUG: ribavirin (RBV)
DRUG: BI 201335 NA high
DRUG: BI 201335 NA low
DRUG: BI 201335 NA high placebo
DRUG: BI 201335 NA high
DRUG: Placebo

Sponsor

Boehringer Ingelheim